Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
43 results about "DU145" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
DU145 (DU-145) is a human prostate cancer cell line. DU145, PC3, and LNCaP are considered to be the standard prostate cancer cell lines used in therapeutic research. The DU145 cell line was derived from a central nervous system metastasis, of primary prostate adenocarcinoma origin, removed during a parieto-occipital craniotomy. DU145 are not hormone-sensitive and do not express prostate-specific antigen (PSA). DU145 cells have moderate metastatic potential compared to PC3 cells, which have high metastatic potential. DU145 cells are androgen receptor positive.
Crown ether cyclic quinazoline compound, preparation method therefor and application thereof in preparing tumor therapy and imaging drug
InactiveCN105384745AGood antitumor activityGood tumor imagingOrganic chemistryRadioactive preparation carriersTumor therapyIsotope
The invention relates to a crown ether cyclic quinazoline derivative and medicinal salts thereof using in tumor therapy and imaging. The crown ether cyclic quinazoline compound is characterized in that a 2-, 3-, 4- substituted aniline is disposed at one end; a 6-, 7- substituted crown ether cyclic quinazoline structure is disposed at the other end; the substituent group R1 is located on the fourth-position aniline of a quinazoline mother ring and is 2-, 3-, 4- substituted alkoxy; and the crown ether cycle is located at the 6, 7 position of the mother ring, and is a 9-crown-3, 12-crown-4 and 15-crown-5, and the structural formula is formula I. The experimental result of antitumor activity in vitro of nonradioactive isotope labeling compounds shows that the compounds are good in inhibitory effect for four kind of cancer cells namely HepG2, A549, sy5y and DU145, and have the potential as cancer treatment medicine; and the body distribution experiment of 18F or 125I labeling compounds show that the compounds are higher in ingestion and certain detention in tumors and faster in blood clearance and have potential applied to tumor imaging.
Owner:BEIJING NORMAL UNIVERSITY
Substituted benzofuran derivative, preparation and application thereof in preparing antitumor drug
InactiveCN108976187AGood antitumor activityLow acute toxicityOrganic active ingredientsGroup 5/15 element organic compoundsSolubilityChemical structure
The invention provides a substituted benzofuran derivative. A chemical structure of the derivative is as shown in general formula I. The invention further provides a preparation method of the formulaI, the preparation method is as shown in the following reaction formula described in the specification, wherein R and R' are defined the same as the specification. In-vitro proliferation inhibition experiment researches of human tumor cells show that the substituted benzofuran derivative has excellent inhibition effects on tumor cells such as human hepatoma cells HLF, human intestinal cancer cellsHCT116, human breast cancer cells MDA-MB-231, human prostate cancer cells DU145, human melanoma cells A375, human colon cancer cells Lovo, human kidney cancer cells 786-o, human chronic myeloid leukemia cells K562, human gastric cancer cells MGC-803, human pancreatic cancer cells PANC-1, can be used for preparing an anti-tumor drug, has low acute toxicity and good water solubility, and has good clinical application prospects. The preparation method provided by the invention is suitable for industrial production.
Owner:SHANGHAI QINGDONG BIOTECH CO LTD
Application of bixanthone compound FLBG-1108 or its medicinal salt in preparing anticancer medicaments
InactiveCN102440985APrevent proliferationHas anticancer effectOrganic active ingredientsRespiratory disorderCytotoxicityOncology
The invention discloses application of a bixanthone compound FLBG-1108 or its medicinal salt in preparing anticancer medicaments. The invention, by means of experiments, finds that the bixanthone compound FLBG-1108 has an obvious inhibition effect on propagation of human non-small cell lung cancer H520, A549, H549, 1299, human breast cancer cell MCF7, human prostatic cancer cell PC3, LNcaP, DU145, as well as human intestinal cancer cell SW480 and HT-2P, can selectively inhibit the propagation of the human lung cancer cell H520, and presents good time and concentration dependence. After 48h of action, the IC50 value is 2.90 micrometers, which shows no cytotoxicity to a normal kidney epidermal cell. Further, the bixanthone compound FLBG-1108 is found to play an effective role in inducing apoptosis of the lung cancer cell H520, preventing propagation of cancer cells but showing no toxicity, and can specifically block the cell cycle of the lung cancer cell H520 in S stage, thus inhibiting the propagation of cancer cells. Therefore, the bixanthone compound FLBG-1108 can be developed into novel candidate medicaments with an anticancer effect, especially an anti-lung cancer effect.
Owner:SHENZHEN XIANHU BOTANICAL GARDEN ADMINISTRATION
Application of nano-microsphere containing orlistat in preparing antineoplastic drugs
ActiveCN108578390AHigh encapsulation efficiencyPromote absorptionOrganic active ingredientsPharmaceutical non-active ingredients2-methacryloyloxyethyl phosphorylcholinePhosphorylcholine
The invention relates to the technical field of medicines, and in particular to an application of nano-microsphere containing orlistat in preparing antineoplastic drugs. The nano-microsphere consistsof the orlistat as well as any copolymer which is selected from a vitamin A methacrylate-2-methacryloyloxyethyl phosphorylcholine copolymer, a vitamin E methacrylate-2-methacryloyloxyethyl phosphorylcholine copolymer and a vitamin D methacrylate-2-methacryloyloxyethyl phosphorylcholine copolymer. Based upon in vitro test results, it is indicated that antineoplastic activity of the nano-microsphereprovided by the invention on human prostate cancer cells DU145, human melanoma cells A375 and human pancreatic cancer cell lines bxpc-3 is obviously higher than that caused by independent administration of the orlistat, and the antineoplastic activity is better than that of control nano-microsphere which is prepared by taking PMB30 as a carrier as well as nano-microsphere which contains the orlistat and polyethylene glycol-polycaprolactone.
Owner:ZHONGSHAN WANHAN PHARM CO LTD
Using Cdc6 as therapeutic, prognostic and diagnostic targets for cell growth/proliferation
Using Cdc6 as therapeutic, prognostic and diagnostic targets for cell growth / proliferation. The unique features of Cdc6 allow anti-Cdc6 treatments to have affect on cancer cells, not on normal cells. Antisense anti-Cdc6 DNA technology is used to test Cdc6 as a target for growth inhibition and shows that the abrogation of Cdc6 mRNA in rapid cell results in death of prostate PC-3, DU145 and LNCaP cancer cells. The study demonstrated the abrogation of Cdc6 mRNA functions in prostate cancer cells could be an extremely effective way to block the cancer cell proliferation. Anti-Cdc6 treatment can be used alone, in combination, or in synergy with currently used therapeutic drugs or radiation therapies. Thus, the Cdc6 gene, mRNA and protein can also be a useful marker for diagnosis, prognosis, or therapy of cell proliferation.
Owner:JONG AMBROSE Y
Aegiceras corniculatum stem ethyl acetate extract and preparation method and application thereof to prostatic cancer treatment
InactiveCN107174594AInhibition of clonogenicityProliferation inhibitoryUrinary disorderAntineoplastic agentsWater bathsEthyl acetate
The invention discloses an aegiceras corniculatum stem ethyl acetate extract and a preparation method thereof. The method includes: soaking aegiceras corniculatum stems into ethanol to obtain aegiceras corniculatum stem ethanol extract; after volatilization of ethanol in the aegiceras corniculatum stem ethanol extract, adding petroleum ether for extraction to obtain a lower water phase; adding ethyl acetate into the lower water phase, continuing extraction to obtain upper ethyl acetate part extract, and performing water bath drying to obtain the aegiceras corniculatum stem ethyl acetate extract. According to in-vitro molecular biological experiment researches, the aegiceras corniculatum stem ethyl acetate extract has an anti-proliferation effect on human prostatic cancer cells PC3 and DU145 and is capable of evidently inhibiting clone formation of the human prostatic cancer cells PC3 and DU145. Therefore, the aegiceras corniculatum stem ethyl acetate extract has a potential application prospect in preparation of medicines for treating prostatic cancer and can be used for preparation of the medicines for treating prostatic cancer. Deeply developing the aegiceras corniculatum stem ethyl acetate extract can expand an aegiceras corniculatum utilization range to create a novel approach for cancer treatment.
Owner:GUANGXI UNIV OF CHINESE MEDICINE
Lead compound for targeted human FKBP51 protein and screening method and application thereof
InactiveCN105902537AStrong off-target effectCompound screeningOrganic active ingredientsProstate cancer cellProtein target
The invention provides a lead compound for a targeted human FKBP51 protein and a screening method and application thereof, belonging to the technical field of biochemical pharmacy. According to the lead compound and the screening method and application thereof, an FK1 structural domain of FKBP51 is used as a receptor; FK506 of the FKBP51 is selected to be combined with a sack; molecular docking is performed by using a Glide program; 150 small molecular compounds are obtained by virtual screening from more than 1.5 million of compounds and are used for fluorescence quenching experiments; according to the experiments, a combination action of the compounds and the FK1 is verified, and the binding property of a target protein and compounds with a strong docking effect is researched; two kinds of cells LNCaP and DU145 are selected to verify the cell viability of screened small molecular compounds resisting prostate cancer; meanwhile, the structural biology research on a compound formed by the FKBP51 and small molecular lead compounds is performed. According to the lead compound provided by the invention, a cell model and a mouse model of CRPC (Castration Resistant Prostate Cancer) are established, the effectiveness of the lead compound to the CRPC is evaluated, and an action mechanism and a rule of the lead compound and the target protein are explained at the molecular level; a foundation is provided for researching and developing new drugs for treating common prostate cancer and the CRPC.
Owner:LANZHOU UNIVERSITY
Application of bixanthone compound FLBG-1108 or its pharmaceutical salts in preparation of anti-cancer drugs
ActiveCN103263409BPrevent proliferationHas anticancer effectOrganic active ingredientsAntineoplastic agentsCytotoxicityHuman breast
The invention discloses an application of bixanthone compound FLBG-1108 or its pharmaceutical salts in the preparation of anti-cancer drugs. It is found in the invention through experiments that the bixanthone compound FLBG-1108 has an obvious inhibitory effect on the multiplication of human non-small cells lung cancer cells H520, A549, H549, 1299, a human breast cancer cell MCF7, human prostatic cancer cells PC3, LNcaP, and DU145 and human intestinal cancer cells SW480 and HT-2P. The multiplication of human lung cancer cells H520 can be inhibited selectively by the bixanthone compound FLBG-1108. The good time and the concentration dependence can be presented. The value of IC50 after 48 h action is 2.90 muM. The cytotoxicity is not expressed at this concentration on normal renal epidermal cells. Further, the bixanthone compound FLBG-1108 can effectively induce the apoptosis of lung cancer cells H520 and prevent the multiplication of cancer cells. Meanwhile, no toxicity will be presented. The bixanthone compound FLBG-1108 can specifically interdict the cell cycle of lung cancer cells H520 in S phase and can therefore inhibit the multiplication of cancer cells. Therefore, the bixanthone compound FLBG-1108 can be developed into a new candidate drug with an anti-cancer effect especially an anti-lung cancer effect.
Owner:SHENZHEN XIANHU BOTANICAL GARDEN ADMINISTRATION
Application of bixanthone compound FLBG-1108 or its pharmaceutical salts in preparation of anti-cancer drugs
ActiveCN103263409APrevent proliferationHas anticancer effectOrganic active ingredientsAntineoplastic agentsCytotoxicityHuman breast
The invention discloses an application of bixanthone compound FLBG-1108 or its pharmaceutical salts in the preparation of anti-cancer drugs. It is found in the invention through experiments that the bixanthone compound FLBG-1108 has an obvious inhibitory effect on the multiplication of human non-small cells lung cancer cells H520, A549, H549, 1299, a human breast cancer cell MCF7, human prostatic cancer cells PC3, LNcaP, and DU145 and human intestinal cancer cells SW480 and HT-2P. The multiplication of human lung cancer cells H520 can be inhibited selectively by the bixanthone compound FLBG-1108. The good time and the concentration dependence can be presented. The value of IC50 after 48 h action is 2.90 muM. The cytotoxicity is not expressed at this concentration on normal renal epidermal cells. Further, the bixanthone compound FLBG-1108 can effectively induce the apoptosis of lung cancer cells H520 and prevent the multiplication of cancer cells. Meanwhile, no toxicity will be presented. The bixanthone compound FLBG-1108 can specifically interdict the cell cycle of lung cancer cells H520 in S phase and can therefore inhibit the multiplication of cancer cells. Therefore, the bixanthone compound FLBG-1108 can be developed into a new candidate drug with an anti-cancer effect especially an anti-lung cancer effect.
Owner:SHENZHEN XIANHU BOTANICAL GARDEN ADMINISTRATION
Lead compound using human FKBP51 protein as target as well as screening method and application thereof
ActiveCN105963301AStrong off-target effectOrganic active ingredientsOrganic chemistryLead compoundMacromolecular docking
The invention provides a lead compound using human FKBP51 protein as a target as well as a screening method and an application thereof, and belongs to the field of biochemical pharmacy technology. A FK1 domain of the FKBP51 protein is used as a receptor, a FK506 binding pocket of the receptor is selected, a Glide program is used for carrying out molecular docking, 150 small molecule compounds are obtained by virtual screening from more than 1.50 million compounds, and fluorescence quenching experiments are carried out for checking binding effects between the compounds and FK1; binding characteristics between the target protein and the compounds with high docking effects are researched, activities of the screened small molecule compounds against prostate cancer cells are checked by using two kinds of selected cells including LNCaP and DU145, and at the same time structural biology researches are carried out for compounds formed by FKBP51 and the small molecule lead compounds. The invention also establishes a cell model and a mice model of CRPC, effectiveness of the lead compounds on CRPC are evaluated, mechanisms and rules of action between the lead compounds and the target protein on molecular level are illustrated, and a foundation is provided for research and development of new drugs for treating common prostate cancer and CRPC.
Owner:LANZHOU UNIVERSITY
Application of saccharide coupled-1, 2, 3-triazole substituted polycyclic aromatic hydrocarbon derivative in preparation of anti-cancer drug
The invention discloses the application of a saccharide coupled-1, 2, 3-triazole substituted polycyclic aromatic hydrocarbon derivative in the preparation of an anti-cancer drug. The structure of thesaccharide coupled-1, 2, 3-triazole substituted polycyclic aromatic hydrocarbon derivative is shown as the formula (I). A pharmacology experiment proves that the saccharide coupled-1, 2, 3-triazole substituted polycyclic aromatic hydrocarbon derivative has different degrees of inhibiting effects on lung cancer (H460), gastric cancer (HGC27), myeloma (H929), cervical cancer (Hela), liver cancer (HepG2), prostatic cancer (DU145) and colon cancer (HT29).
Owner:TIANJIN UNIV
Construction method of prostate cancer radiation tolerance cell strain
InactiveCN112662629AGood cell modelHigh homologyDead animal preservationElectrical/wave energy microorganism treatmentProstate cancer cellDU145
The invention discloses a construction method and application of a human prostate cancer radiation tolerance cell strain. The method comprises the following steps: taking a human prostate cancer cell strain DU145 in an exponential growth phase, and inoculating the human prostate cancer cell strain DU145 into a 60mm culture dish according to the density of 5 * 10<5> cells per dish; when the cells grow to 60%, carrying out X-ray irradiation, wherein the irradiation dose is 4Gy; continuously culturing the cells until the density reaches 90%, digesting with pancreatin, counting, and inoculating into a 60mm culture dish according to the density of 5 * 10 <5> cells per dish; repeating the steps of irradiation and culture, and continuing stable passage for 30 days when the accumulated irradiation dose of the cells reaches 60Gy; and after the human prostate cancer radiation-tolerant cell strain which grows stably, is subjected to passage and is resuscitated is obtained, cryopreservingthe cells in a liquid nitrogen tank in time. Small-dose X-rays are selected for cell irradiation, and the method is characterized in that the clinical radiation treatment process is simulated, the irradiation dose is small, the cell survival rate is high, and the cell drug resistance is stable.
Owner:LANZHOU UNIVERSITY
PSMA activated antitumor prodrug CPT-X, and preparation method and applications thereof
The invention provides a compound having a general structure formula 1, and a preparation method and applications thereof in preparation of antitumor drugs. The PSMA activated prodrug CPT-HT-J-ZLn shows strong cytotoxic selectivity on tumor cells with PSMA positive expression and PSMA negative expression and is more active to tumor cells LNCaP-FGC with PSMA positive expression than to tumor cellsPC-3, DU145, HepG2, Hela and MCF-7 with PSMA negative expression; and the activity of the compound CPT-HT-J-ZLn12 to the LNCaP-FGC (IC50=1.00+ / -0.20 [mu]M)(PSMA<+>) respectively is 40, 40, 21, 5 and 40 times that of the cells HepG2 (IC50>40.00 [mu]M), Hela (IC50>40.00 [mu]M), MCF-7 (IC50=21.68+ / -4.96 [mu]M), DU145 (IC50=5.40+ / -1.22 [mu]M) and PC-3 (IC50=42.96+ / -3.69 [mu]M) with PSMA negative expression.
Owner:薪火炙药(北京)科技有限公司
DI- and Tri-Cationic Glycosylated Antitumor Ether Lipids, L-Gucosylated Gaels and Rhamnose-Linked Gaels as Cytotoxic Agents Against Epithelial Cancer Cells and Cancer Stem Cells
Glycosylated Antitumor Ether Lipids (GAELs) kill cancer cells by a nonapoptotic pathway which is an attractive strategy to avoid resistance. To further optimize the antitumor effect, we prepared various analogs of di-, and tri-cationic GAEL analogs differing in the nature of the sugar (D-giucose or L-glucose), the anomeric linkage as well as position of the glycerolipid moiety. The di- and tri-cationic GAELs were synthesized and their in vitro anticancer properties were evaluated against drug resistant and aggressively growing cancer cell lines derived from human breast, prostate, pancreatic and ovarian cancers. The most potent dicationic GAEL analogs were also studied against cancer stem cells obtained from breast BT 474, prostate DU145 and ovarian A2780cp cell lines. Our results indicate that the number of positive charges, the position of the amino substituents and the nature of the sugar have significant effects on the anticancer activities of these compounds. The most active analog kill 50% of the cells at concentration range of 0.5-5 μM and 90% of the cells at the concentration of 1-10 μM depending on type of cancer cells.
Owner:UNIVERSITY OF MANITOBA
Benzoquinone compound and use thereof for preparing anti-tumour drug
InactiveCN103113335BSignificant in vitro cytotoxic activityStrong inhibitory activityOrganic active ingredientsOrganic chemistryProstate cancer cellNasopharyngeal carcinoma
The invention belongs to the field of pharmacy and relates to a benzoquinone compound and use thereof for preparing an anti-tumour drug, in particular to preparation of Arnebinone B and use thereof for resisting lung cancer, prostatic cancer and nasopharynx cancer. The benzoquinone compound provided by the invention is Arnebinone B, which is separated from arnebiae. In-vitro anti-tumour activity experimental results show that the median inhibitory concentration of Arnebinone B on lung carcinoma cell A549 is 4.86 mu g / ml, the median inhibitory concentration of Arnebinone B on prostate cancer cell DU145 is 5.16 mu g / ml, the median inhibitory concentration of Arnebinone B on nasopharyngeal carcinoma cell KB is 5.2 mu g / ml, and the median inhibitory concentration of Arnebinone B on KB drug-resistant strain KB-VIN is 4.98 mu g / ml. The result shows that Arnebinone B can be used for preparing the anti-tumour drug, in particular drugs for treating lung cancer, prostatic cancer and nasopharynx cancer.
Owner:FUDAN UNIV
Lead compounds, screening methods and applications targeting human fkbp51 protein
ActiveCN105963301BStrong off-target effectOrganic active ingredientsOrganic chemistryProstate cancer cellProtein target
Owner:LANZHOU UNIVERSITY
Preparation method and application of Shenmei Yangwei granule
ActiveCN105056105BHigh in active ingredientsDigestive systemGranular deliveryIon-exchange resinElecampane
The invention belongs to the field of a traditional Chinese medicinal preparation, and in particular provides a preparation method of a Shenmei stomach-nourishing particle (containing ginseng and dark plum). The stomach-nourishing particle is prepared from the following medicinal raw materials: 140g of radix glehniae, 105g of safflower, 175g of dandelion, 175g of radices paeoniae alba, 117g of hawthorn, 105g of curcuma zedoary, 140g of radix salviae miltiorrhizae, 117g of radix angelicae sinensis, 35g of dark plum, 70g of elecampane inla root and 70g of liquorice root by virtue of macroporous resin, cation exchange resin and anion exchange resin, so that content is greatly improved and dosage is reduced. The invention also provides application of the Shenmei stomach-nourishing particle in preparing medicines for inhibiting proliferation of human prostatic cancer cells DU145.
Owner:NANJING TONGRENTANG PHARM CO LTD
Application of circular RNA-circEXOC6B in inhibiting metastasis of prostate cancer
PendingCN114410789AInhibit migrationInhibition of migration assayOrganic active ingredientsMicrobiological testing/measurementProstate cancer cellOncology
The invention relates to an application of circular RNA-circEXOC6B (Ribonucleic Acid-CircEXOC6B) in inhibiting metastasis of prostatic cancer. Low expression of circEXOC6B in prostate cancer cells and prostate cancer tissues is found for the first time, stable transfection prostate cancer DU145 and PC-3 cell lines of the over-expressed circEXOC6B are further constructed, cell Transwell migration experiments and invasion experiments find that the over-expressed circEXOC6B can significantly inhibit migration and invasion of prostate cancer cells, in addition, a nude mouse pulmonary metastatic tumor model is constructed, and the model is used for screening prostate cancer cells and prostate cancer tissues. It is found that when the circEXOC6B overexpressed DU145 cells are injected into nude mouse bodies through caudal veins, in-vivo prostatic cancer metastasis can be remarkably inhibited. Therefore, circEXOC6B can be used as a new therapeutic target for prostatic cancer, and reference is provided for development of prostatic cancer drugs.
Owner:复旦大学附属金山医院(上海市金山区眼病防治所上海市金山区核化伤害应急救治中心)
Novel application of Java brucea fruit oil emulsion injection to anticancer aspect
ActiveCN101879202ALow cytotoxicitySmall toxicityEmulsion deliveryAntineoplastic agentsHl 60 cellOil emulsion
Owner:SHENYANG PHARMA UNIVERSITY
Method for adjusting prostate cancer tumor angiogenesis by utilizing miR-203/SNAI2 axis
InactiveCN110117651AReduce cumulative tube lengthEnhanced inhibitory effectOrganic active ingredientsMicrobiological testing/measurementProstate cancer cellTumor angiogenesis
The invention relates to the technical field of molecular detection, in particular to a method for detection of microRNAs and treatment of prostate cancers (PCa). The invention provides influence of an miR-203 / SNAI2 axis on in-vitro and in-vivo biological characteristics of the prostate cancers. Particularly, miR-203 is expressed in DU145 and PC3 cells to reduce angiogenesis, and the inhibitory effect of the miR-203 can be improved through the expression of the miR-203 and SNAI2. The miR-203 inhibits the formation of endothelial cells of prostate cancer cells and angiogenesis.
Owner:天津科美生物技术有限公司
Anti-prostate cancer compound and preparation method thereof
InactiveCN112759540AGood killing effectEasy to prepareOrganic chemistryUrinary disorderProstate cancer cellDU145
Owner:重庆知翔科技有限公司
Gene-recombined TNF-alpha derivative RMP16 and preparation method and application thereof
ActiveCN104177489AImprove biological activityImprove stabilityBacteriaPeptide/protein ingredientsSide effectEstramustine
The invention discloses a gene-recombined TNF-alpha derivative RMP16 and a preparation method and application thereof. The RMP16 is obtained through gene recombination, has higher stability and physiological activity in blood compared with those of the natural TNF-alpha, can remarkably inhibit the growth of cells of tumors, such as prostatic carcinoma Du145, lymphoma Raji, leukemia K562, cervical carcinoma HeLa, breast cancer MCF-7 and the like, has an especially outstanding inhibition effect on DU145, can inhibit the growth of remarkable Du145 cell transplantable tumor, and has pharmacodynamic effects similar to those of estramustine; proved by results of tests on nude mice with Du145 cell transplantable tumor, the recombinant polypeptide RMP16 has toxic and side effects, which are obviously lower than those of estramustine, and is free from obvious toxic and side effect performance. The gene-recombined TNF-alpha derivative RMP16 can be applied to the preparation of drugs with the functions of treating the tumors, such as prostatic carcinoma, lymphoma, chronic myelogenous leukemia, cervical carcinoma, breast cancer and the like.
Owner:JINAN UNIVERSITY
A stable cell line of du145 with low expression of gfpt1 and its construction and application
ActiveCN109913498BEffective treatmentActivation activityGenetic engineeringFermentationDU145Staining
Owner:DALIAN INST OF CHEM PHYSICS CHINESE ACAD OF SCI
Dual inhibitor targeting JAK/STAT and NF kappa B signal channels and application thereof
ActiveCN113082036AHas inhibitory effectAlleviation of symptoms in mice with septic shockAntibacterial agentsOrganic active ingredientsDU145Dual inhibitor
The invention provides a dual inhibitor targeting JAK / STAT and NF kappa B signal channels and an application thereof, and belongs to the technical field of biology. The invention provides a novel dual inhibitor L971-0101 capable of targeting JAK / STAT and NF kappa B signal channels, which has an inhibition effect on phosphorylation of STAT3 in a prostate cancer cell line DU145 and TNF alpha-induced I kappa B degradation in a cervical cancer cell line Hela, in addition, the dual inhibitor L971-0101 can relieve symptoms of LPS-induced sepsis shock mice in vivo, and effectively improves the survival rate of the mice, therefore, the product can be used as a potential inflammation inhibitor and has the potential of treating septicemia.
Owner:OCEAN UNIV OF CHINA +1
A traditional Chinese medicine composition for treating prostate cancer and its preparation method
ActiveCN107096003BPrevent proliferationPromote apoptosisUnknown materialsAntineoplastic agentsProstate cancer cellDU145
The invention discloses a traditional Chinese medicine composition used for treating prostatic cancer. The traditional Chinese medicine composition used for treating prostatic cancer comprises, by weight, 9 to 30 parts of Radix Astragali, 6 to 15 parts of gen-seng, 6 to 15 parts of Chinese wolfberry, 6 to 15 parts of epimeddium, 3 to 10 parts of rhizoma curcumae longae, 9 to 20 parts of radix salviae miltiorrhizae, 9 to 20 parts of Rhizoma Paridis, 3 to 10 parts of scorpion, and 6 to 15 parts of mythic fungus. The traditional Chinese medicine composition is suitable for patients with treating prostatic cancer caused by deficient root with overdo superficial, possesses inhibition effects on propagation and promotion effect on apoptosis of castration-resistant prostate cancer cell PC3 and DU145. The invention also discloses a drug of the traditional Chinese medicine composition used for treating prostatic cancer, and a preparation method of the drug.
Owner:GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE
Method for adjusting in-vitro migration of prostatic cancer cells through miR-203/SNAI2 axis
InactiveCN110117650APromote migrationImprove migration abilityOrganic active ingredientsGenetic material ingredientsDU145Prostate cancer cell
The invention relates to the technical field of molecular detection, in particular to a method for detecting and treating prostatic cancers (PCa) through microRNA. The invention provides influence ofan miR-203 / SNAI2 axis on in-vitro biological characteristics of the prostatic cancers, in particular to expression of miR-203 in DU145 and PC3 cells to inhibit expression of SNAI2. The miR-203 inhibits proliferation and migration of the prostatic cancer cells and the formation of endothelial cells and tumor stem cells.
Owner:天津科美生物技术有限公司
Application of marsdenia tenacissima extract
PendingCN112022891AGood inhibitory effectEnhanced inhibitory effectAntineoplastic agentsPlant ingredientsProstate cancer cellOncology
The invention discloses an application of a marsdenia tenacissima extract in preparation of a medicine for treating prostatic cancer, an application of the marsdenia tenacissima extract in preparationof a medicine for inhibiting cell growth of prostatic cancer PC3 and DU145, an application of the marsdenia tenacissima extract in preparation of a medicine for inhibiting cell migration of the prostatic cancer PC3 and DU145, an application of the marsdenia tenacissima extract in preparation of a medicine for inducing cell apoptosis of the prostate cancer DU145, an application of the marsdenia tenacissima extract in preparation of a medicine for inhibiting GSK-3[beta] / STAT3 signal axis, and an application of the marsdenia tenacissima extract in preparation of a medicine for up-regulating expression of Cytochrome C, Cleaved Caspase 3 and Cleaved Caspase 7. A marsdenia tenacissima extract medicine preparation is an injection preparation or a tablet. The application range of the marsdenia tenacissima extract is widened, and a new way is provided for application of the marsdenia tenacissima extract.
Owner:GUANGXI MEDICAL UNIVERSITY
Application of rhizoma paridis extract in preparation of drugs for treating human prostate cancer
InactiveCN108853128AGrowth inhibitionHigh expressionOrganic active ingredientsUrinary disorderDU145Autophagosome
The invention discloses application of a rhizoma paridis extract in preparation of drugs for treating human prostate cancer. According to the application, experiments shows that polyphyllin I has an inhibition effect on the human prostate cancer DU145 and PC3 cell lines, and the inhibition effect is improved along with the increase of dosage and time; in addition, the polyphyllin I can induce theincrease of autophagosomes and promote the expression increase of human prostate cancer cells LC3B-II, and therefore the growth of xenografted tumors of DU145 cells can be inhibited; and the polyphyllin I is a potential, novel and effective anti-prostate-cancer drug and can be used for preparing drugs for treating the human prostate cancer, a new way for treating the human prostate cancer is opened up, and the medical application range of the polyphyllin I is widened.
Owner:HUBEI UNIVERSITY OF MEDICINE
Aegiceras corniculatum leaf n-butyl alcohol extract and preparation method and application thereof to prostatic cancer treatment
ActiveCN107174595AInhibit transferProliferation inhibitoryUrinary disorderAntineoplastic agentsWater bathsLymphatic Spread
The invention discloses an aegiceras corniculatum leaf n-butyl alcohol extract and a preparation method thereof. The method includes: soaking aegiceras corniculatum leaves into ethanol to obtain aegiceras corniculatum leaf ethanol extract; after volatilization of ethanol in the aegiceras corniculatum leaf ethanol extract, adding petroleum ether for extraction to obtain a lower water phase; adding ethyl acetate into the lower water phase to extract, then adding n-butyl alcohol after the lower water phase is obtained, continuing extraction to obtain upper n-butyl alcohol part extract, and performing water bath drying to obtain the aegiceras corniculatum leaf n-butyl alcohol extract. According to in-vitro molecular biological experiment researches, the aegiceras corniculatum leaf n-butyl alcohol extract has an anti-proliferation effect on human prostatic cancer cells PC3 and DU145 and is capable of evidently inhibiting metastasis of the human prostatic cancer cells PC3 and DU145. Therefore, the aegiceras corniculatum leaf n-butyl alcohol extract has a potential application prospect in preparation of medicines for treating prostatic cancer and can be used for preparation of the medicines for treating prostatic cancer. Deeply developing the aegiceras corniculatum leaf n-butyl alcohol extract can expand an aegiceras corniculatum utilization range to create a novel approach for cancer treatment.
Owner:GUANGXI UNIV OF CHINESE MEDICINE
Aegiceras corniculatum leaf petroleum ether extract and its preparation method and use in treatment on prostatic cancer
InactiveCN107095889AProliferative inhibitory clonogenicityInhibition of clonogenicityAntineoplastic agentsPlant ingredientsDU145Water baths
The invention provides aegiceras corniculatum leaf petroleum ether extract and a preparation method thereof. The preparation method comprises adding aegiceras corniculatum leaves into ethanol, soaking the aegiceras corniculatum leaves to obtain ethanol total extract of aegiceras corniculatum leaves, volatilizing the ethanol in the ethanol total extract, adding petroleum ether into the total extract, carrying out extraction, collecting petroleum ether extract in the upper layer, carrying out water bath treatment, and carrying out drying. An in-vitro molecular biology experiment result shows that the petroleum ether extract of the aegiceras corniculatum leaves can inhibit proliferation of human prostatic cancer cells PC3 and DU145 and significantly inhibit cloning formation of human prostatic cancer cells PC3 and DU145. Therefore, the petroleum ether extract of the aegiceras corniculatum leaves has a potential application prospect in preparation of drugs for treating prostatic cancer and can be used for preparation of an anti-prostatic cancer drug. Deep development of the aegiceras corniculatum leaf petroleum ether extract can enlarge a use range of aegiceras corniculatum and provide a novel approach for cancer treatment.
Owner:GUANGXI UNIV OF CHINESE MEDICINE
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com